Metronomic chemotherapy with taxanes may reverse taxane resistance by anti-angiogenic effect

ISRCTN ISRCTN27587187
DOI https://doi.org/10.1186/ISRCTN27587187
Secondary identifying numbers RGZHSM 005
Submission date
18/08/2009
Registration date
27/08/2009
Last edited
27/08/2009
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Filip Geurs
Scientific

Ziekenhuislaan 100
Halle
1500
Belgium

Study information

Study designSingle arm single centre non-randomised phase II feasibility trial
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details provided in the interventions section to request a patient information sheet
Scientific titleThe combination of metronomic taxanes and valproic acid and enoxaparin decreases tumour marker levels in taxane refractory tumour types: a single arm, single centre, non-randomised, phase II feasibility trial
Study acronymMTAX
Study objectivesMetronomic chemotherapy with taxanes creates an important anti-angiogenic effect. This anti-angiogenic effect is enhanced by histone deacetylase inhibitors like valproic acid. The intracellular accumulation of chemotherapy is facilitated by enoxaparin.
Ethics approval(s)Institutional Review Board of the Regionaal Ziekenhuis Sint Maria approved on the 7th April 2009
Health condition(s) or problem(s) studiedAdvanced solid tumours, metastatic disease
InterventionPatients will receive paclitaxel 20 mg/m^2/day on days 1 - 5 and 7 - 12 of a 21-day cycle. In patients with prior docetaxel exposure this becomes docetaxel 6 mg/m^2 on day 1 - 5 and 7 - 12 of a 21-day cycle. In both groups valproic acid 2 x 500 mg per day is added, and enoxaparin 40 mg is injected subcutaneously together with the chemotherapy.

Total duration of treatment: 6 months; follow-up duration: one year.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II
Drug / device / biological / vaccine name(s)Paclitaxel, docetaxel, valproic acid, enoxaparin
Primary outcome measureTumour marker decrease (carcinoembryonic antigen [CEA], prostate specific antigen [PSA], cancer antigen 15-3 [CA 15-3]) as a marker of the anti-angiogenic potential, after week 1, and thereafter every three weeks.
Secondary outcome measuresTumour response, assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST), measured at week 19.
Overall study start date10/04/2009
Completion date01/09/2010

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants24
Key inclusion criteria1. Histologically or cytologically proven metastatic solid tumours. Patients must have disease which has failed standard taxane based chemotherapy.
2. Greater than or equal to 18 years of age, either sex
3. Eastern Cooperative Oncology Group performance status (ECOG PS) less than or equal to 3
4. Life expectancy greater than or equal to 8 weeks
5. Evaluable (based on radiological assessments or tumour markers) disease
6. Recovered (i.e., to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] Version 3.0 Grade less than or equal to 1) from all toxicities associated with previous chemotherapy or radiotherapy (exception: patients may enter with continuing alopecia irrespective of CTCAE grade). The following intervals between starting last treatment must elapse:
6.1. Chemotherapy: at least 4 weeks
6.2. Mitomycin C or a nitrosourea: at least 6 weeks
6.3. Targeted therapy: at least 2 weeks or 2 half-lives, whichever is longer
6.4. Biologics: at least 4 weeks
Key exclusion criteria1. Pregnant women, women who are lactating, or women of childbearing potential who are not currently on effective means of birth control
2. History of QT/QTc prolongation, clinically significant ventricular tachycardia, ventricular fibrillation, heart block, myocardial infarction within 1 year, congestive heart failure New York Heart Association Class III or IV, unstable angina, angina within 6 months, or other evidence of clinically significant coronary artery disease
3. Active, ongoing infection, including viral hepatitis
4. Undergone major surgery within the last 4 weeks
5. Organ transplant recipients
6. New brain metastasis. Patients with treated (surgically excised or irradiated) and stable brain metastases are eligible as long as the treatment was at least 4 weeks prior to initiation of study drug and baseline brain computed tomography (CT) with contrast or magnetic resonance imaging (MRI) within 2 weeks of initiation of study drug is negative for new brain metastases.
7. Patients who have been on other experimental clinical trials of investigational agents within the last 28 days
Date of first enrolment10/04/2009
Date of final enrolment01/09/2010

Locations

Countries of recruitment

  • Belgium

Study participating centre

Ziekenhuislaan 100
Halle
1500
Belgium

Sponsor information

St Mary Hospital (Sint-Maria Ziekenhuis) (Belgium)
Hospital/treatment centre

c/o Mr Jan Claes
Directiesecretariaat
Ziekenhuislaan 100
Halle
1500
Belgium

Website http://www.regzhsintmaria.be

Funders

Funder type

Industry

GEURS FILIP BVBA (Belgium)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan